Efatutazone is under clinical development by Daiichi Sankyo and currently in Phase II for Anaplastic Thyroid Cancer. According to GlobalData, Phase II drugs for Anaplastic Thyroid Cancer have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Efatutazone’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Efatutazone (CS-7017) is under development for the treatment of myxoid liposarcoma and anaplastic thyroid cancer. The drug candidate is administered orally as a film coated tablet. It binds to peroxisome proliferation-activated receptor gamma (PPAR-gamma). It was also under development for the treatment of colorectal and non-small-cell lung cancer.
Daiichi Sankyo overview
Daiichi Sankyo is a holding company, which carries out the research, development, manufacture, and marketing of pharmaceutical products. The company offers a wide range of prescription drugs, over the counter (OTC) drugs, vaccines, and others. Its portfolio encompasses medicines for cardiovascular, neurological, nephrological, diabetic, metabolic, and infectious diseases, and various types of cancers. Besides cancer, the company’s other research areas include rare diseases and immune disorders. Daiichi Sankyo sells its products through its group companies, and an extensive network of medical representatives. It has operations in North America, South and Central America, Europe, and Asia. Daiichi Sankyo is headquartered in Tokyo, Japan.
For a complete picture of Efatutazone’s drug-specific PTSR and LoA scores, buy the report here.